Bioactivity | AChE/BuChE-IN-5(compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE)(IC50=46.9 nM) and butyryl cholinesterase (BuChE)(IC50=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research[1]. |
Invitro | AChE/BuChE-IN-5 可抑制乙酰胆碱酯酶(AChE)(IC50=46.9 nM)和丁基胆碱酯酶(BuChE))(IC50=46.9 nM) , 其抑制效果优于已知的双抑制剂利 Rivastigmine 在 AD 病动物模型中(HY-17368)[1]。AChE/BuChE-IN-5 对 BuChE 的选择性高于 AChE, 选择性指数(SI)为 0.07, 表明其对 BuChE 的抑制作用更强。[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> AChE/BuChE-IN-5 相关抗体: |
In Vivo | AChE/BuChE-IN-5(1 mg/kg, ip.; 14 天) 具有神经保护, 抗氧化和抗凋亡作用在 AD 动物模型中[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
Formula | C19H14N4O |
Molar Mass | 314.34 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Zaafar D, et al. Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies[J]. International Journal of Biological Macromolecules, 2024: 131740. |